2019
|
Sign up to set email alerts
|

Abstract: Aims To investigate cardiovascular (CV) safety and event rates for dapagliflozin versus other glucose‐lowering drugs (GLDs) in a real‐world type 2 diabetes population after applying the main inclusion criteria and outcomes from the DECLARE‐TIMI 58 study. Methods Patients with new initiation of dapagliflozin and/or other GLDs were identified in Swedish nationwide healthcare registries for the period 2013 to 2016. Patients were included if they met the main DECLARE‐TIMI 5… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

12
77
0

Year Published

2019
2019
2020
2020

Publication Types

Select...
2

Relationship

1
1

Authors

Journals

citations
Cited by 53 publications
(89 citation statements)
references
References 42 publications
(89 reference statements)
12
77
0
Order By: Relevance
“…In this nationwide, observational, real‐world study, a novel approach was used to evaluate the estimated total healthcare costs for patients with T2D who initiated treatment with either dapagliflozin or a non‐SGLT‐2i oGLD in a population with a patient profile to similar to that of the DECLARE‐TIMI 58 trial . This DECLARE‐like population, defined by applying the main eligibility criteria from the DECLARE‐TIMI 58 trial to a real‐world population, has been described previously …”
Section: Discussionmentioning
confidence: 94%
See 3 more Smart Citations
“…In this nationwide, observational, real‐world study, a novel approach was used to evaluate the estimated total healthcare costs for patients with T2D who initiated treatment with either dapagliflozin or a non‐SGLT‐2i oGLD in a population with a patient profile to similar to that of the DECLARE‐TIMI 58 trial . This DECLARE‐like population, defined by applying the main eligibility criteria from the DECLARE‐TIMI 58 trial to a real‐world population, has been described previously …”
Section: Discussionmentioning
confidence: 94%
“…Unlike cost‐effectiveness analyses, the analysis reported here does not include a measure of the outcomes, for example, Quality Adjusted Life Years (QALYs). However, as previously shown in a DECLARE‐like population, treatment with dapagliflozin has beneficial CV effects compared with treatment with oGLDs, and this would lead to a QALY benefit. When considered along with this QALY benefit, the cost neutrality between dapagliflozin and oGLDs observed in this study indicates that dapagliflozin is cost‐effective compared with oGLDs.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…The availability of sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors confirmed the role of impaired tubulo‐glomerular balance in the constitution of diabetic kidney disease and hypervolaemia (which favours heart failure in patients with diabetes). In the EMPA‐REG OUTCOME study and in subsequent outcome studies of similar drugs (canagliflozin and dapagliflozin), SGLT2 inhibitors prevented albuminuria and renal failure. Glomerular filtration rate (GFR) dropped initially, and then flattened, as preglomerular resistance was reduced .…”
Section: Mechanisms Behind High Bp In People With Diabetesmentioning
confidence: 99%